AstraZeneca's New Weight-Loss Pill Challenges Market Titans

AstraZeneca's experimental obesity pill, elecoglipron, demonstrated notable weight loss in trials, challenging market leaders like Novo Nordisk and Eli Lilly. Patients lost up to 11.8% of body weight over 36 weeks. The company aims to advance to late-stage trials and envisions it as a key component in its obesity strategy.

AstraZeneca has announced significant weight loss results from its mid-stage trials of the experimental obesity pill, elecoglipron. During the study, patients experienced an average weight loss of 10.5% over 26 weeks, with results improving to 11.8% over 36 weeks, according to data presented at the American Diabetes Association meeting in New Orleans.

The pharmaceutical giant is positioning this once-daily pill to compete with Novo Nordisk and Eli Lilly's market-dominating treatments. If approved, elecoglipron will enter late-stage trials, hoping to match or surpass the 14% weight loss achieved by Novo’s Wegovy and the 12% reduction recorded by Lilly’s Foundayo.

AstraZeneca's Sharon Barr highlighted the company's ambition to pair elecoglipron with other medications to treat obesity and related health conditions like diabetes and heart disease. The trial, enrolling 310 adults, noted that common side effects were gastrointestinal. The company licensed the drug from China's Eccogene for around $2 billion in late 2023.